C4 Therapeutics: Funding, Investors & Team (Aug 2026)

C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.

C4 Therapeutics has raised $150M across 1 round on record. The most recent is an undisclosed round of $150M announced in Jun 2020.

C4 Therapeutics' most recent funding round on record is an undisclosed round of $150M, announced in Jun 2020.

Andrew Phillips is listed as CEO at C4 Therapeutics.

C4 Therapeutics is based in Cambridge, Massachusetts, United States.

C4 Therapeutics is in the 101-250 employee band.

C4 Therapeutics' latest round of $150M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.